Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD557 in GERD with persistent symptoms on PPIs
NCT01370863Phase 2Terminated
- Sponsor
- Takeda
- Start
- Dec 2010
- Primary completion
- May 2012
- Modality
- Small Molecules
- Countries
- 6
01
Overview
A Phase 2 trial of velusetrag in gastroesophageal reflux disease (GERD), sponsored by Takeda. Started Dec 2010; status: terminated.
02
Drugs
velusetrag
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT01370863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01370863.